The putative impact on cancer hallmarks, through AT1 receptor blockade or activation of the ACE2/Ang-(1–7)/Mas receptor axis, has been linked to reduced tumor growth and vascularization in lung cancer, thus fostering the need for clinical studies. The gene discussed is AGTR1; the disease is lung carcinoma.